Thomas Herrmann

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · The Lancet Oncology · 2009 · 960 citations

Medicine, Oncology, Chemotherapy +16

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Niels Halama, Inka Zoernig, Anna Berthel et al. · Cancer Cell · 2016 · 494 citations · Full text

Medicine, Immunology, Oncology +11

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 414 citations · Full text

Medicine, Oncology, Pharmacology +14

Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron

Sven G. Gehrke, Hasan Kulaksiz, Thomas Herrmann et al. · Blood · 2003 · 242 citations · Full text

Medicine, Biochemistry, Molecular Biology +15

Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4

Katrin Milger, Thomas Herrmann, Christiane Becker et al. · Journal of Cell Science · 2006 · 228 citations

Life Sciences, Cell Biology, Molecular Biology +16